



GOOD PEOPLE
for **GOOD HEALTH**

February 5, 2026

National Stock Exchange of India Limited
Exchange Plaza, 5th Floor, Plot No. C/1,
G-Block, Bandra Kurla Complex,
Bandra (E), Mumbai – 400051.

Stock Symbol: JBCHEPHARM

Dear Sir,

Sub.: Outcome of meeting of the Board of Directors

Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), 2015 (“Listing Regulations”) read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 and Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated September 09, 2015

This is to inform you that the Board of directors of the Company at its meeting held today has *inter-alia* approved :

1. the appointment of Mr. Kaushal Solanki as the Chief Financial Officer of the Company and Key Managerial Personnel with effect from February 5, 2026.

The details as required under Regulation 30 of the Listing Regulations and the SEBI Master Circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, as amended from time to time are provided in Annexure I.

2. declaration of interim dividend of Rs. 12.70 per equity share of face value of Re. 1 (1270%) for financial year 2025-26. The dividend will be credited to the shareholders on or after February 25, 2026.

The meeting commenced at 5.34 p.m. and was concluded at 6.01 p.m.



GOOD PEOPLE
for GOOD HEALTH

We request you to take the above on record.

Thanking you,

Yours faithfully,

For J.B. Chemicals & Pharmaceuticals Limited

Sandeep Phadnis
Vice President – Secretarial
& Company Secretary



GOOD PEOPLE
for GOOD HEALTH

Annexure I

Sr. No.	Disclosure requirement	Details
1	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise	Appointment
2	Date of appointment/ re-appointment /cessation (as applicable) & term of appointment/ re-appointment	Mr. Kaushal Solanki is appointed as Chief Financial Officer of the Company and Key Managerial Personnel with effect from February 5, 2026
3	Brief profile	Mr. Kaushal Solanki is a Chartered Accountant with over 30 years of experience in finance and had been associated with Torrent Pharmaceuticals Limited since October 2003. He has held several senior leadership roles in Torrent Pharmaceuticals Limited across financial reporting, internal audit, tax, international business finance, plant finance, and R&D finance, and has been closely involved in M&A evaluations.
4	Disclosure of relationships between directors	Not applicable